Pfizer tightened its full-year earnings forecast to between $2.23 and $2.27 per share from its prior outlook of $2.20 to $2.30

Pfizer reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets(...)

 Pfizer has approached Actavis to express its interest in an acquisition that could allow the US drugmaker to move overseas and reduce taxes. Photo: Bloomberg

Ireland is back at the centre of the controversy over corporate inversion as it emerged that drug giant Pfizer has approached Irish-headquartered Acta(...)

Leif Johansson, non-executive chairman of AstraZeneca: Pfizer had “failed to make a compelling strategic, business or value case” for what would be the biggest foreign takeover of a British company.

AstraZeneca has rejected a “final” £69.4 billion takeover approach from Pfizer, triggering the biggest one-day drop in its shares on record.The Britis(...)

A ‘final’ offer from Pfizer was rejected by AstraZeneca’s board today. Photograph: Stefan Wermuth/Files/Reuters

AstraZeneca has rejected a sweetened and “final” offer from Pfizer, leaving it uncertain if the US drugmaker would pull off its plan to create the wor(...)

Image of the week: Pfizer coins it Pfizer chief executive Ian Read (in the red tie) is seen here arriving to give evidence at a British parliamen(...)

(From the right) Dr Mikael Dolsten, president, worldwide research and development of Pfizer, Ian Read, chairman and chief executive, Pfizer and Dr Rod MacKenzie, group senior vice president, and head of Pfizer pharma therapeutics research and development, Pfizer, give evidence to the Science and Technology Committee at the House of Commons, London. Photo: PA Wire

Merging Pfizer and AstraZeneca could create “a powerhouse of science” delivering “much better outcomes” for patients suffering from illnesses includin(...)

Ian Read, chairman and chief executive of Pfizer leaves Portcullis House after attending a parliamentary business and enterprise committee hearing on the possible takeover of AstraZeneca, in London.

As Westminster grillings go, the enquiry into Pfizer’s proposed £63 billion (€77 billion) takeover bid for AstraZeneca was a relatively restrained aff(...)

(left to right) Frank D’Amelio, executive vice president, business operations and chief financial officer, Ian Read, chairman and chief executive and Jonathan Emms, UK managing director, all of Pfizer, give evidence to the Commons Business, Innovation and Skills Committee, at the House of Commons, London. Photograph: PA

US drugmaker Pfizer suggested it could raise its proposed $106 billion offer if AstraZeneca engaged in talks, as its boss was grilled by UK politician(...)

Ian Read, chief executive officer of Pfizer Inc, faces faces tough questions from British lawmakers. Photograph: Bloomberg

Pfizer defended the business case behind its plan to acquire AstraZeneca yesterday and questioned the UK drugmaker’s ability to stand alone for much l(...)

The US group has apparently promised to retain 20 per cent of the enlarged group’s R&D personnel in the UK.

Pfizer’s focus on keeping the British onside as it attempts to end the independent existence of its second-largest pharma group runs the risk of creat(...)